The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
Accelerator™ Drug Development: Streamlining preclinical pathways for a fast transition to First-in-Human trials
Case study
For biotechnology drug developers, everything that happens between preclinical development and first-in-human (FIH) trials can mean the difference between progress and stagnation—from navigating regulatory complexities to optimizing study design. Without the right strategy, early-stage biotech innovators risk missing key clinical milestones and losing investor confidence.
One biotechnology drug developer recently faced this challenge while advancing a novel therapeutic to clinical testing. Their API characterization and release methods were insufficiently defined, risking an 18-month delay and over $1M in added costs. At the same time, inefficiencies in their FIH study design and site selection threatened to extend timelines even further.
Download our case study to see how they achieved success with Thermo Fisher Scientific’s Accelerator™ Drug Development —delivering greater speed, simplicity, and scalability.
